Circ_PRKCI is upregulated in PCa tissues, and its level is linked to metastasis rate in PCa patients. It triggers proliferative and metastatic potentials in PCa by downregulating miR-24-3p.
 Circ_PRKCI is upregulated in PCa tissues, and its level is linked to metastasis rate in PCa patients. It triggers proliferative and metastatic potentials in PCa by downregulating miR-24-3p.
  This paper compares individual radiation therapy techniques used for prostate cancer and their benefits in clinical practice.
 
  We retrospectively analyzed 921 patients with localized prostate tumors treated between 1997 and 2012. We divided the patients into four groups according to the selected treatment technique (conformal radiation therapy [3DCRT], intensity-modulated radiation therapy [IMRT], image-guided radiation therapy [IGRT], and volumetric-modulated arc therapy [VMAT]) and evaluated the incidence of acute and chronic gastrointestinal (GI) and genitourinary (GU) toxicity.
 
  The incidence of grade 2 or greater acute GU and GI toxicity was significantly higher among techniques other than IGRT (p˂0.001). We found the same results in the case of grade 3 or greater acute GU toxicity (p˂0.001). Grade 3 or higher acute GI toxicity occurred only in one patient treated by 3DCRT. Cumulative late GI toxicity of grade 2 or higher and grade 3 or higher was recorded over 3 years significantly more frequently among non-IGRT techniques as compared to IGRT (p˂0.001). As regards GU toxicity, we found significantly higher incidence only for grade 2 or higher (p˂0.001), not for grade 3 or higher.  https://www.selleckchem.com/products/jzl184.html  No occurrence of grade 4 toxicity was recorded. The greatest incidence of patients without acute and chronic GI/GU toxicity was recorded in connection with VMAT.
 
  IGRT demonstrated a pronounced reduction in acute and chronic GU and GI toxicity as compared to non-IGRT techniques in the treatment of localized prostate cancer.
 IGRT demonstrated a pronounced reduction in acute and chronic GU and GI toxicity as compared to non-IGRT techniques in the treatment of localized prostate cancer.
  The purpose of this study was to compare the clinical efficacy and safety of S-1 + oxaliplatin (SOX) chemotherapy regimen combined with trastuzumab and irinotecan + cisplatin (IP) chemotherapy regimen combined with trastuzumab in treating human epidermal growth factor receptor 2 (HER-2)-positive advanced gastric cancer.
 
  A total of 138 patients with HER-2-positive advanced gastric cancer were divided into SOX group (SOX chemotherapy regimen combined with trastuzumab; n=69) and IP group (IP chemotherapy regimen combined with trastuzumab; n=69). Then, the clinical efficacy, incidence rate of adverse reactions, quality-of-life score and other indicators were compared between the two groups of patients. Additionally, the levels of myeloid-related protein-14 (MRP-14), stromal cell-derived factor-1 (SDF-1), fibroblast-specific protein-1 (FSP-1) and CXC chemokine receptor-4 (CXCR4) in peripheral blood and the changes in neovascularization markers were detected, and the survival of patients was followed up and rece serum tumor marker levels in patients, delays tumor progression, and results in tolerable adverse reactions. Therefore, it is worthy of application in clinical practice.
  Gastric cancer, which is derived from gastric mucosal epithelial cells, is a representative solid tumour, and more than 1 million cases are diagnosed worldwide each year. However, treatment methods and therapeutics for gastric cancer are limited, and further research is needed to develop novel strategies.
 
  In this experiment, we studied the effect of catalpol from the extract of Dihuang from traditional Chinese medicine on gastric cancer cells.
 
  The results showed that catalpol led to a dose-dependent reduction in gastric cancer cell proliferation. When the promotion of autophagy by catalpol was inhibited, the proapoptotic effects of catalpol on gastric cancer cells were enhanced. Bax, an apoptosis-related marker, was upregulated in catalpol-treated cells, and its expression was increased in the group treated with catalpol in combination with an inhibitor compared to the group treated with catalpol alone. Opposite results were obtained with BCL-2 inhibition. Flow cytometry showed that apoptosis rates were higher in cells treated with a combination of autophagy inhibitors. Accumulation of reactive oxygen species (ROS) in gastric cancer cells showed the group treated with the combination of catalpol and an inhibitor enhanced ROS production. Transwell assays showed that catalpol plus autophagy inhibitors exerted a stronger inhibitory effect on the migration ability of AGS cells than catalpol alone.
 
  In summary, the above results indicate that inhibition of catalpol-induced autophagy could better promote the apoptosis of gastric cancer cells.
 In summary, the above results indicate that inhibition of catalpol-induced autophagy could better promote the apoptosis of gastric cancer cells.
  To investigate the clinical efficacy and safety of apatinib combined with tegafur-gimeracil-oteracil potassium (S-1) in the second-line treatment of advanced gastric cancer.
 
  A total of 126 patients with advanced gastric cancer admitted to our hospital from January 2017 to September 2018 were enrolled as the research objects, none of whom underwent surgery. For these patients, second-line treatment was recommended due to the failure of first-line treatment. According to the different therapeutic options, patients were categorized into S-1 group (n=63) and Apatinib group (S-1 combined with apatinib, n=63), and drugs were administered orally. The clinical efficacy, serological indicators, adverse reactions and immune function were compared between the two groups. Besides, the survival status of patients was recorded through follow-up.
 
  In S-1 group and Apatinib group, the objective response rate (ORR) was 30.2% (19/63) vs. 50.8% (32/63) and the disease control rate (DCR) was 54.0% (34/63) vs. 74.6% (47/63),f life, reduce the serum tumor marker levels and prolong the OS of patients, but it cannot extend the PFS.
 In the second-line treatment of advanced gastric cancer, apatinib combined with S-1 is superior to S-1 alone in term of clinical efficacy, and its adverse reactions can be tolerated. Apatinib combined with S-1 can prominently improve the quality of life, reduce the serum tumor marker levels and prolong the OS of patients, but it cannot extend the PFS.